OIPE
NOV 13 2007
IAP32
PATENT & TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
11874-044-999	10/602,142
APPLICANT	**CONFIRMATION NO.**
Sommadossi *et al.*	8280
FILING DATE	**ART UNIT**
June 20, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A01	RE29,835	11/14/78	Witkowski, et al.	
	A02	3,116,282	12/31/63	Hunter	
	A03	3,798,209	3/19/74	Wilkowski, et al.	
	A04	3,891,623	6/24/75	Vorbruggen, et al.	
	A05	4,209,613	6/24/80	Vorbruggen	
	A06	4,294,766	10/13/81	Schmidt, et al.	
	A07	4,522,811	6/11/85	Eppstein, et al.	
	A08	4,605,659	8/12/86	Verheyden, et al.	
	A09	4,689,404	8/25/87	Kawada, et al.	
	A10	4,754,026	6/28/88	Kawada, et al.	
	A11	4,814,477	3/21/89	Wijnberg, et al.	
	A12	4,880,784	11/14/89	Robins, et al.	
	A13	4,952,740	8/28/90	Juge, et al.	
	A14	4,957,924	9/18/90	Beauchamp	
	A15	5,034,394	7/23/91	Daluge	
	A16	5,122,517	6/16/92	Vince, et al.	
	A17	5,149,794	9/22/92	Yatvin, et al.	
	A18	5,157,027	10/20/92	Biller, et al.	
	A19	5,194,654	3/16/93	Hostetler, et al.	
	A20	5,200,514	4/06/93	Chu	
	A21	5,223,263	6/29/93	Hostetler et al.	
	A22	5,256,641	10/26/93	Yatvin, et al.	
	A23	5,322,955	6/21/94	Matsumoto, et al.	
	A24	5,371,210	12/06/94	Chou, et al.	
	A25	5,372,808	12/13/94	Blatt, et al.	
	A26	5,391,769	2/21/95	Matsumoto, et al.	
	A27	5,401,861	3/28/95	Chou, et al.	
	A28	5,411,947	5/02/95	Hostetler, et al.	
	A29	5,463,092	10/31/95	Hostetler, et al.	
	A30	5,543,389	8/06/96	Yatvin, et al.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A31	5,543,390	8/06/96	Yatvin, et al.	
	A32	5,543,391	8/06/96	Yatvin, et al.	
	A33	5,554,728	9/10/96	Basava, et al.	
	A34	5,606,048	2/25/97	Chou, et al.	
	A35	5,676,942	10/14/97	Testa, et al.	
	A36	5,696,277	12/09/97	Hostetler, et al.	
	A37	5,738,845	4/14/98	Imakawa	
	A38	5,744,600	4/28/98	Mansuri, et al.	
	A39	5,750,676	5/12/98	Vorbruggen, et al.	
	A40	5,763,418	6/09/98	Matsuda, et al.	
	A41	5,780,617	7/14/98	Van den Bosch, et al.	
	A42	5,789,608	8/04/98	Glazier	
	A43	5,821,357	10/13/98	Chou, et al.	
	A44	5,830,455	11/3/98	Valtuena, et al.	
	A45	5,849,696	12/15/98	Chretien, et al.	
	A46	5,908,621	6/1/99	Glue, et al.	
	A47	5,928,636	7/27/99	Alber, et al.	
	A48	5,942,223	8/24/99	Bazer, et al.	
	A49	5,977,325	11/2/99	McCarthy, et al.	
	A50	5,980,884	11/9/99	Blatt, et al.	
	A51	6,002,029	12/14/99	Hostetler, et al.	
	A52	6,063,628	5/16/00	Loeb, et al.	
	A53	6,140,310	10/31/00	Glazier	
	A54	6,153,594	11/28/00	Borretzen, et al.	
	A55	6,156,501	12/05/00	McGall, et al.	
	A56	6,172,046	1/09/01	Albrecht	
	A57	6,248,878	6/19/01	Matulic-Adamic, et al.	
	A58	6,252,060	6/26/01	Hostetler	
	A59	6,271,212	8/07/01	Chu, et al.	
	A60	6,277,830	8/21/01	Ganguly, et al.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A61	6,312,662	11/06/01	Erion, et al.	
	A62	6,369,040	4/09/02	Acevedo, et al.	
	A63	6,436,437	8/20/02	Yatvin, et al.	
	A64	6,448,392	9/10/02	Hostetler, et al.	
	A65	6,455,508	9/24/02	Ramasamy, et al.	
	A66	6,472,373	10/29/02	Albrecht	
	A67	6,566,344	5/20/03	Gosselin, et al.	
	A68	6,566,365	5/20/03	Storer	
	A69	6,569,837	5/27/03	Gosselin, et al.	
	A70	6,599,887	7/29/03	Hostetler, et al.	
	A71	6,605,614	8/12/03	Bachand, et al.	
	A72	6,752,981	6/22/04	Erion, et al.	
	A73	6,784,161	8/31/04	Ismaili, et al.	
	A74	6,787,526	9/7/04	Bryant, et al.	
	A75	6,812,219	11/2/04	LaColla, et al.	
	A76	6,815,542	11/9/04	Hong, et al.	
	A77	6,831,069	12/14/04	Tam, et al.	
	A78	6,875,751	4/5/05	Imbach, et al.	
	A79	6,908,924	6/21/05	Watanabe, et al.	
	A80	6,914,054	7/05/05	Sommadossi, et al.	
	A81	6,927,291	8/9/05	Jin, et al.	
	A82	6,946,450	9/20/05	Gosselin, et al.	
	A83	6,965,033	11/15/05	Jiang, et al.	
	A84	7,056,895	6/6/06	Ramasamy, et al.	
	A85	7,094,770	8/22/06	Watanabe, et al.	
	A86	7,101,861	9/05/06	Sommadossi, et al.	
	A87	7,105,493	9/12/06	Sommadossi, et al.	
	A88	7,105,499	9/12/06	Carroll, et al.	
	A89	7,125,855	10/24/06	Bhat, et al.	
	A90	7,148,206	12/12/06	Sommadossi, et al.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A91	7,157,441	1/02/07	Sommadossi, et al.	
	A92	7,163,929	1/16/07	Sommadossi, et al.	
	A93	7,169,766	1/30/07	Sommadossi, et al.	
	A94	7,202,224	4/10/07	Eldrup, et al.	
	A95	2002/0035085	3/21/02	Somadossi, et al.	
	A96	2002/0052345	5/2/02	Erion, et al.	
	A97	2002/0055473	5/9/02	Ganguly, et al.	
	A98	2002/0099072	7/25/02	Bachand, et al.	
	A99	2002/0127203	9/12/02	Albrecht	
	A100	2002/0173490	11/21/02	Jiang, et al.	
	A101	2003/0039630	2/27/03	Albrecht	
	A102	2003/0053986	3/20/03	Zahm	
	A103	2003/0055013	3/20/03	Brass	
	A104	2003/0083306	5/1/03	Imbach, et al.	
	A105	2003/0124512	7/3/03	Styuver	
	A106	2003/0225028	12/4/03	Gosselin, et al.	
	A107	2003/0225037	12/4/03	Storer, et al.	
	A108	2004/0002596	1/1/04	Hong, et al.	
	A109	2004/0063622	4/1/04	Sommadossi, et al.	
	A110	2004/0077587	4/22/04	Sommadossi, et al.	
	A111	2004/0097461	5/20/04	Sommadossi, et al.	
	A112	2004/0097462	5/20/04	Sommadossi, et al.	
	A113	2004/0101535	5/27/04	Sommadossi, et al.	
	A114	2004/0102414	5/27/04	Sommadossi, et al.	
	A115	2005/0124532	6/09/05	Sommadossi, et al.	
	A116	2004/0229839	11/18/04	Babu, et al.	
	A117	2004/0248844	12/9/04	Ismaili, et al.	
	A118	2004/0259934	12/23/04	Olsen, et al.	
	A119	2004/0266723	12/30/04	Otto, et al.	
	A120	2004/0266996	12/30/04	Microbiologica Quimica E Farmaceutica Ltd., Brazil	

LAI-2913274v1

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A121	2005/0009737	1/13/05	Clark, et al.	
	A122	2005/0020825	1/27/05	Storer, et al.	
	A123	2005/0031588	2/10/05	Sommadossi, et al.	
	A124	2005/0038240	2/17/05	Connolly, et al.	
	A125	2005/0090463	4/28/05	Roberts, et al.	
	A126	2005/0101550	5/12/05	Roberts, et al.	
	A127	2005/0107312	5/19/05	Keicher, et al.	
	A128	2005/0113330	5/26/05	Imbach, et al.	
	A129	2005/0137141	6/23/05	Hilfinger, et al.	
	A130	2005/0215511	9/29/05	Roberts, et al.	
	A131	2006/0040890	3/23/06	Martin; Joseph Armstrong, et al.	
	A132	2006/0111311	5/25/06	Keicher, et al.	
	A133	2006/0194835	8/31/06	Dugourd, et al.	
	A134	2006/0241064	10/26/06	Roberts, et al.	
	A135	2007/0015905	1/18/07	LaColla, et al.	
	A136	2007/0203334	8/30/07	Mayes, et al.	
	A137	10/845,976	5/14/04	Storer, et al.	
	A138	11/005,443	12/06/04	Gosselin, et al.	
	A139	11/516,928	9/06/06	Sommadossi, et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
	B01	CA 2252144	4/16/00	Miller, et al.		
	B02	DD 140254	2/20/80	Barwolff, et al.	English Abstract Provided	
	B03	DE 3,512,781	10/17/85	Soc. Nat. Elf Aquitaine	English Abstract Provided	
	B04	DE 42 24 737	2/03/94	Schott	English Abstract Provided	
	B05	DE 102005012681	09/21/06	Weber, Lutz	English Abstract Provided	
	B06	EP 0 180 276	12/19/88	Stamicarbon B.V.		
	B07	EP 0 352 248	1/24/90	Medivir AB		

LAI-2913274v1

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
	B08	EP 0,350,287	9/27/00	Chimerix		
	B09	EP 0 526 655	2/10/93	Japan Tobacco Inc.		
	B10	EP 0 553 358	8/04/93	Japan Tobacco Inc.		
	B11	EP 0 587 364	3/16/94	Britton, et al.		
	B12	EP 0,650,371	11/15/00	State of Oregon		
	B13	EP 0 742 287	11/13/96	McGall, et al.		
	B14	EP 0 747 389	12/11/96	Taiho Pharmaceutical Co Ltd		
	B15	GB 1,187,824	5/02/66	Walton		
	B16	GB 1,542,442	3/21/79	Schering AG		
	B17	JP 09059292	3/04/97	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B18	JP 2091022	3/30/90	Univ. of Minnesota	English Abstract Provided	
	B19	JP 61212592	9/20/86	Tokyo Tanabe Co. Ltd.	English Abstract Provided	
	B20	JP 06135988	5/17/94	Toagosei Chimical Ind., Ltd.	English Abstract Provided	
	B21	JP 06211890	8/02/94	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B22	JP 06293645	10/21/94	Jpn. Kokai Tokkyo Koho	English Abstract Provided	
	B23	JP 61263995	11/21/86	Takeda Chemical Ind., Ltd.	English Abstract Provided	
	B24	WO 89/02733	4/06/89	Regents of the Univ. of California		
	B25	WO 90/00555	1/25/90	Vical, Inc.		
	B26	WO 91/16920	11/14/91	Vical, Inc.		
	B27	WO 91/18914	12/12/91	Vical, Inc.		
	B28	WO 91/19721	12/26/91	Glazier		
	B29	WO 93/00910	1/21/93	Vical, Inc.		
	B30	WO 94/001117	1/20/94	Koszalka, et al.		
	B31	WO 94/26273	11/24/94	Hostetler		
	B32	WO 96/15132	5/23/96	Regents of the Univ. of California		
	B33	WO 99/15194	4/01/99	Schering Corporation		
	B34	WO 99/023104	5/14/99	Klecker, et al.		
	B35	WO 99/45016	9/10/99	Metabasis Therapeutics, Inc.		
	B36	WO 99/052514	10/21/99	Eli Lilly and Co.		
	B37	WO 99/59621	11/25/99	Schering Corporation		

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
	B38	WO 99/64016	12/16/99	Hoffman-La Roche AG		
	B39	WO 00/025799	5/11/00	Gosselin, et al.		
	B40	WO 00/37110	6/29/00	Schering Corporation		
	B41	WO 00/52015	9/08/00	Metabasis Therapeutics, Inc.		
	B42	WO 01/18013	3/15/01	Metabasis Therapeutics, Inc.		
	B43	WO 01/47935	7/05/01	Metabasis Therapeutics, Inc.		
	B44	WO 01/049700	07/12/01	Biochem Pharma Inc., Can.		
	B45	WO 01/81359	11/01/01	Schering Corporation		
	B46	WO 02/32414	4/25/02	Schering Corporation		
	B47	WO 03/24461	3/27/03	Schering Corporation		
	B48	WO 03/039523	5/15/03	Wengel		
	B49	WO 03/068244	8/21/03	Merck & Co.; Isis Pharmaceuticals Inc.		
	B50	WO 03/099840	12/04/03	Eldrup, et al.		
	B51	WO 03/100017	12/04/03	Eldrup, et al.		
	B52	WO 03/105770	12/24/03	Eldrup		
	B53	WO 04/003000	1/8/04	Idenix Pharma.; Univ. D.S. Cagliari		
	B54	WO 04/003138	1/08/04	Merck & Co., Isis Pharmaceutical		
	B55	WO 04/041203	5/21/04	Xenoport, Inc., USA		
	B56	WO 04/043977	5/27/04	Prakush, et al.		
	B57	WO 04/043978	5/27/04	Baker, et al.		
	B58	WO 04/044132	5/27/04	Baker, et al.		
	B59	WO 04/046331	6/03/04	Idenix Cayman Limited		
	B60	WO 04/052899	6/24/04	Idenix Cayman Limited		
	B61	WO 04/058792	7/15/04	Idenix Cayman Limited		
	B62	WO 04/065398	8/5/04	Ribapharm, Inc.		
	B63	WO 04/072090	8/26/04	Merck & Co., Inc.		
	B64	WO 04/080466	9/23/04	Ribapharm, Inc.		
	B65	WO 04/084796	10/07/04	Pharmasset, Ltd.		
	B66	WO 04/096149	11/11/04	Idenix Cayman Limited		
	B67	WO 04/106356	12/9/04	Syddansk Universitet		

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
	B68	WO 05/003147	1/13/05	Pharmasset, Ltd.		
	B69	WO 05/012327	2/10/05	University College Cardiff Consultants Limted		
	B70	WO 05/020884	3/10/05	CENT NAT RECH SCI.		
	B71	WO 05/020885	3/10/05	Isis Pharmaceuticals, Inc., USA		
	B72	WO 05/021568	3/10/05	Biota, Inc.		
	B73	WO 05/030258	4/07/05	Dihedron Corp.		
	B74	WO 05/042556	5/12/05	Genelabs Technologies, Inc., USA		
	B75	WO 05/123087	12/29/05	Merck & Co., Inc.		
	B76	WO 06/002231	1/05/06	Biocryst Pharmaceuticals, Inc.		
	B77	WO 06/012078	2/02/06	Merck & Co., Inc.		
	B78	WO 06/012440	2/02/06	Pharmasset, Ltd.		
	B79	WO 06/016930	2/16/06	Intermune, Inc.		
	B80	WO 06/037028	4/06/06	CENT NAT RECH SCI		
	B81	WO 06/037227	4/13/06	Migenix Inc., Can.		
	B82	WO 06/063717	6/22/06	Universitaet Karlsruhe		
	B83	WO 06/065335	6/22/06	Merck & Co. Inc., USA		
	B84	WO 06/097323	9/21/06	Weber, Lutz		
	B85	WO 06/100087	9/28/06	Novartis A.G.		
	B86	WO 06/121820	11/16/06	Valeant Research & Development		
	B87	WO 06/130532	12/07/06	Novartis AG, Switz.		
	B88	WO 07/011777	1/25/07	Novartis A.-G., Switz.		
	B89	WO 07/025304	1/03/07	University of Oxford; Idenix Phamaceuticals; et al.		

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	Alt, et al., "Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Ptent and Specific Inhibitors of Hepatitis C Viral Translation." Arch. Virol. (1997) 142: 589-599.	
	C02	Alt, et al., "Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides," Hepatology, 22:707-717 (1995).	
	C03	Awano, et al., "Nucleosides and Nucleotides, Part 144 Synthesis and Antiviral Activity of 5-Substituted (2's)-2'-	

LAI-2913274v1

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Deoxy-2' –C-Methylycytidines and –Urdines," Archiv Der Pharmazie, VCH Verlagsgesellschaft Mbh, Weinheim, DE, vol. 329, February 1, 1996, (1996-02-01), pp. 66-72.	
	C04	Battaglia, et al., "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection." *Ann. Pharmacother*, 34: 487-494 (2000).	
	C05	Beigelman, et al., "Functionally complete analogs of nucleosides. The use of D-gluclose for the synthesis of 2-C-methyl-D-ribose derivatives and related nucleosides. Biorrganicheskaya Khimiya. 1986, Vol. 12(10), pp. 1359-65.	
	C06	Berenguer, et al., "Hepatitis C Virus in the Transplant Setting." *Antivir. Ther.*, 3 (Suppl. 3): 125-136 (1998).	
	C07	Berman, E., et al., "Synergistic Cytotoxic Effect of Azidothymidine and Recombinant Interferon Alpha on Normal Human Bone Marrow Progenitor Cells," Blood, 74(4):1281-1286 (1989).	
	C08	Bhat, et al., (Oral Session V, Hepatitis C Virus, Flaviviridae, 2003 (Oral Session V, Hepatitis C Virus Flaviviridael 16th International Conference On Antiviral Research (April 27, 2003, Savannah, Ga.); p. A75).	
	C09	Bhopale, Girish Mahadeorao, et al., "Emerging drugs for chronic hepatitis C," Hepatology Research (2005), 32(3), 146-153.	
	C10	Bianco, et al., "Sythesis of a New Carbocyclic Nucleoside Analog." *Tetrahedron Letters*, 38(36): 6433-6436.	
	C11	Billich, et al., "Nucleoside Phosphotransferase from Malt Sprouts." Biol. Chem. Hoppe-Seyler, Vol. 367, pp. 267-278, April 1986.	
	C12	Bio, et al., "Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor." Journal of Organic Chemistry (2004), 69(19), 6257-6266.	
	C13	Bloch, A., et al., "The Role of the 5'-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase," J. Med. Chem., 10(5):908-12 (September 1967).	
	C14	Browne, et al., "2',3'-didehydro-3'-deoxythymidiane (d4T) in Patients with AIDS or AIDS-Related Complex: A Phase I Trial." *J. Infect. Dis.*, 167(1): 21-29 (1993).	
	C15	Bryant, M.L., et al., "Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection," Antimicrobial Agents and Chemotherapy, 45(1):229-235 (January 2001).	
	C16	Cappellacci, et al. "Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of 1' –C-methyl denosine analogues," J. Med. Chem., vol. 45, 2002, pp. 1196-1202.	
	C17	Cappellacci, et al. "Synthesis, Biological Evaluation, and Molecular Modeling of Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists." Journal of Medicinal Chemistry (2005), 48(5), 1550-1562.	
	C18	Carroll, S.S., "Nucleoside analog inhibitors of hepatitis C virus replication," Infectious Disorders: Drug Targets (2006), 6(1), 17-29.	
	C19	Chand, Pooran; et al., "Synthesis of (2S,3S,4R,5R)-2-(4- amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, an analog of potent HCV inhibitor." Collection Symposium Series (2005), 7(Chemistry of Nucleic Acid Components), 329-332.	
	C20	Chiacchio, et al., "Stereoselective synthesis of 2'-amino-2',3'dideoxynucleosides by nitrone 1,3-dipolar cycloaddition: A new efficient entry toward d4T and its 2-methyl analougue," J. Org. Chem., vol. 64, 1999, pp. 28-36.	
	C21	Chiaramonte, et al., "Inhibition of CMP-Sialic Acid Transport into Golgi Vesicles by Nucleoside Monophates." Biochemistry 2001, 40, 14260-14267.	
	C22	Clark, et al., "Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication." Journal of Medicinal Chemistry (2005), 48(17), 5504-5508.	
	C23	Coelmont, Lotte, "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methycytidine, the active component of valopicitabine," Antimicrobial Agents and Chemotherapy (2006), 50(10), 3444-3446.	
	C24	Colacino, "Review article: Mechanisms for the Anti-Hepatitis B Virus Activity and Mitochondrial Toxicity of Fialurdine (FIAU)." *Antiviral Res.*, 29(2-3): 125-39 (1996).	

LAI-2913274v1

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C25	Cook, G.S., "Improving the treatment of hepatitis C infection in the UK," Expert Opinion on Pharmacotherapy, (2007) Vol. 8, No. 2, pp. 183-191.	
	C26	Cornberg, M., et al., "Present and future therapy for hepatitis C virus," Expert review of Anti-Infective Therapy, (2006) Vol. 4, No. 5, pp. 781-793.	
	C27	Cretton-Scott, E., et al., "Pharmacokinetics of B-L-2'-Deoxyctidine Prodrugs in Monkeys," Antiviral res., 50:A44 (2001).	
	C28	Cui, et al., "Cellular and Molecular Events Leading to Mitochondrial Toxicity of l-(2-deoxy-2-fluoro-1-B-D-arabinofuranosyl)-5-iodouracil in Human Liver Cells." *J. clin. Invest.*, 95: 555-563 (1995).	
	C29	Czernecki, S., et al., "Synthesis of 2'-deoxy-2'-spirocyclopropyl cytidine as potential inhibitor of ribonucleotide diphosphate reductase," Can. J. Chem., vol. 71, 1993, pp. 413-416.	
	C30	Dalpiaz, et al., "Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis." European Journal of Pharmacology (2002), 448(2-3), 123-131	
	C31	Davis, "Current Therapy for Chronic Hepatitis C." *Gastroenterology*, 118: S104-S114 (2000).	
	C32	Davis, G.L., "New Therapies: Oral Inhibitors and Immune Modulators," Clinics in Liver Disease, (2006) Vol. 10, No. 4, pp. 867-880.	
	C33	Davisson, V.J., et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," J. Org. Chem., 52(9):1794-1801 (1987).	
	C34	DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, A New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors." *J. Med. Chem.*, 37: 498-511.	
	C35	Ding, et al., "Synthesis of 2'-β-C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 725-727.	
	C36	Ding, et al., "Synthesis of 9-(2-β-C-methyl-β-D-ribofuranosyl)-6- substituted purine derivatives as inhibitors of HCV RNA replication." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 709-713	
	C37	Dornsife, et al., "In Vitro Potency of Inhibition by Antiviral Drugs of Hematopoietic Progenitor Colony Formation Correlates with Exposure at Hemotoxic Levels In Human Immunodeficiency Virus-Positive Human." *Antimicrob. Agents Chemother.*, 40(2): 514-519 (1996).	
	C38	Dutartre, H., et al., "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues," Antimicrobial Agents and Chemotherapy, (2006) Vol. 50, No. 12, pp. 4161-4169.	
	C39	Dymock, et al., "review: Novel Approaches to the Treatment of Hepatitis C Virus Infection." *Antiviral Chemistry & Chemotherapy*, 11(2): 79-95 (2000).	
	C40	Eldrup, et al., Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A75-77.	
	C41	Eldrup, et al., "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication." Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(21), 5284-5297.	
	C42	Eldrup, et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase.", Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(9), 2283-2295.	
	C43	Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 3-fluoro-2'-deoxyuridine 5'-phosphate." *J. Med. Chem.* 26: 1153 (1983).	
	C44	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-oxo-1,3,2-oxazaphosphorinan-2-yl-)-B-D-arabinosyl]adenine and 9-[5'-(2-oxo-1,3,2-dioxazaphosphorinan-2-yl)-B-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[B-D-arabinofuranosyl[adenine 5'-monophosphate." *J. Med. Chem.* 28: 1358-1381 (1985).	
	C45	Feast, A.A.J., et al., "Studies on the D-Glucosaccharinic Acids," Acta Chemica Scandinavica 19(5):1127-1134 (1965).	

LAI-2913274v1

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C46	Ferrari, et al., "Characterization of Soluble Hepatitis C Virus RNA-Dependent RNA Polymerase Expressed in *Escherichia Coli*." *Jounal of Virology*, 73(2), 1649-1654 (1999).	
	C47	Fischl, et al., "Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection who Received Previous Zidovudine Therapy." *Ann. Intern. Med.*, 18(10): 762-769 (1993).	
	C48	Fox, J. J., et al., "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," J. Am. Chem. Soc., 81: 178-187 (January 5, 1959).	
	C49	Franchetti, et al., "Antitumor Activity of C-Methyl-β-D-ribofuranosyladenine Nucleoside Ribonucleotide Reductase Inhibitors." Journal of Medicinal Chemistry (2005), 48(15), 4983-4989.	
	C50	Freed, et al., "Evidence fo Acyloxymethyl Esters of Pyrimidine 5'-deoxyribonucleotides as Extracellular Sources of Active 5'-deoxyribonucleotides in Cultured Cells." *Biochemical Pharmacology*. 38: 3193-3198 (1989).	
	C51	Fujimori, et al., "A Convenient and Stereoselective Synthesis of 2'-Deoxy-[beta]-L-nucleosides," Nucleosides & Nucleotides, 11(2-4), 341-349 (1992); only CAPLUS abstract supplied.	
	C52	Furukawa, Y., et al. "A novel method for synthesis of purine nucleosides using Friedel-Crafts catalysts," Chem. Pharm. Bull., 16(6):1076-1080 (June 1968).	
	C53	Galderisi, U., et al., "Antisense oligonucleoties as therapeutic agents," Journal of Cellular Physiology, 181(2):251-257 (November 1999).	
	C54	Gallo, et al., "2'-C-Methyluridine Phosphoramidite: A New Building Block for the Preparation of RNA Analogues Carrying the 2'-hydroxyl Group." Tetrahedron, 57 (2001), 5707-5713.	
	C55	Girardet, et al., "Synthesis and Cytotoxicity of 4-Amino-5-oxopyrido[2,3-d]pyrimidine Nucleosides." Journal of Medicinal Chemistry (2000), 43(20), 3704-3713.	
	C56	Gretch, D.R., "Use and interpretation of HCV diagonostic tests in the clinical setting." Clinics in Live Disease, November 1997, Vol. 1, No. 3, pp. 547-557.	
	C57	Grouiller, et al., "Structural studies on a psicofuranosyl nucleoside, a potential antiviral agent." J. Pharm. Belg., 47(4), 381-3 (1992).	
	C58	Gunic, et al., "Synthesis and Cytotoxity of 4'-C-and 5'-C-substituted Toyocamycins." *Bioorg. Med. Chem.*, 9:163-170 (2001).	
	C59	Hassan, et al., "Nucleosides and Nucleotides 151: Conversion of (Z)-2'-(Cyanomethylene)-2'-Deoxyuridines into their (E)-Isomers via Addition of Thiophenol to the Cyanomethylene Moiety Followed by Oxidative Syn-elimination Reactions." J. Org. Chem., vol. 61, 1996, pp. 6261-6267.	
	C60	Hassan, et al., "Nucleosides and Nucleotides 156: Chelation-Controlled and Nonchelation-Controlled Diastereofacial Selective Thiophernol Addition Reactions at the 2'-Position of 2'-[(Alkoxycarbonyl)methaylene]-2'-deoxyuridines: Conversion of (Z0-2'[(Alkoxycarbonyl)methylene]-2'-Deoxyuridines into their (E)-Isomers" J. Org. Chem., vol. 62, 1997, pp. 11-17.	
	C61	Hayakawa, et al., "Reaction of organometallic reagents with 2'- and 3'-ketouridine derivatives: synthesis of uracil nucleosides branched at the 2'- and 3'-positions." Chemical & Pharmaceutical Bulletin (1987), 35(6), 2605-8.	
	C62	Hoard, D.E., et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," J. Am Chem. Soc., 87(8):1785-1788 (April 20, 1965).	
	C63	Holy, A., "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides fo the Pyrimidine Series," Collect. Czech. Chem. Commun., 37(12): 4072-4087 (1972).	
	C64	Hossain, et al., "Synthesis of 2'- and 3'-Spiro-isoxazolidine Derivatives of Thymidine & Their Conversions to 2',3'-dideoxy-2', 3'-didehydro-3'-C-substituted nucleosides by Radical Promoted Fragmentation," Tetrahedron Vol. 49, No. 44, pp. 10133-10156, (1993).	
	C65	Hostetler, et al., "Synthesis and Antiretroviral Activity of Phospholipids Analogs of Azidothymidine and Other Antiviral Nucleosides." *J. Biol.Chem.*, 265: 6112-6117 (1990).	
	C66	Hostetler, et al., "Greatly Enhanced Inhibition of Human Immunodeficiency Virus Type I Replication in CEM and HT4-6C Cells by 3'-deoxythymidine Diphosphate Dimyristoylglycerol, a Lipid Prodrug of 3'-	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		deoxythymidine." *Antimicrob. Agents Chemother.*, 36: 2025-2029 (September 1992).	
	C67	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Drived from 2'-deoxy-5-fluorouridine." *J. Med. Chem.* 27:440-444 (1984).	
	C68	Iglesias, et al., "Complete and Regioselective Deacetylation of Peracetylated Uridines Using a Lipase." Biotechnology Letters 22: 361-365, 2000.	
	C69	Iimori, et al., "2'-C-, 3'-C-, and 5'-C-Methylsangivamycins: conformational lock with the methyl group." Tetrahedron Letters (1991), 32(49), 7273-6.	
	C70	Iimori, et al., "A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases." Nucleic Acids Symposium Series (1992), 27(Nineteenth Symposium on Nucleic Acids Chemistry, 1992), 169-70.	
	C71	Ikegashira, K., et al., "Discovery of conformationally constrained tetracylic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors," Journal of Medicinal Chemistry, (30 Nov 2006) Vol. 449, No. 24, pp. 6950-6953.	
	C72	Imai, K., et al., "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides." J. Org. Chem., 34(6): 1547-1550 (June 1969).	
	C73	Jones, et al., "Oxidation of Carbohydrates by the Sulfoxide-Carbodiimide and Related Methods," *Methods in Carbohydrate Chemistry*, Whisler, R.L. and Moffatt, J.L. Eds; Academic Press: New York, 1972; 315-322.	
	C74	Jones, et al., "4'-substituted Nucleosides. 5. Hydroxymethylation of Nucleoside 5'-aldehydes." *J. Org. Chem.*, 44: 1309-1317 (1979).	
	C75	Kakefuda, et al., "Nucleosides and nucleotides. 120. Stereoselective radical deoxygenation of tert-alcohols in the sugar moiety of nucleosides: synthesis of 2',3'-dideoxy-2'-C-methyl- and -2'-C-ethynyl-β-D-threo-pentofuranosyl pyrimidines and adenine as potential antiviral and antitumor agents." Tetrahedron (1993), 49(38), 8513-28	
	C76	Kamaike, K., et al., "An efficient method for the synthesis of [4-15N]cytidine, 2'-deoxy[4-15N]cytidine,]6-15N]adenosine, and 2'-deoxy[6-15N]adenosine derivatives," Nuclesodies and Nucleotides, 15(1-3_: 749-769 (1996).	
	C77	Kaneko, M., et al., "A convenient synthesis of cytosine nucleosides," Chem. Pharm. Bull., 20:1050-1053 (1972).	
	C78	Kempe, T., et al., "Selective 2'-Benzoylation at the Cis 2', 3'-diols of Protected Ribonucleosides. New Solid Phase Synthesis of RNA and DNA-RNA Mixtures," Nucleic Acids Res., 10(21):6695-6714 (November 11, 1982).	
	C79	Kerr, S.G., et al., "N-(Dialkylamino)Methylene Derivatives of 2'-Deoxycytidine and Arabinocytidine: Physicochemical Studies for Potential Prodrug Applications," J. Pharm. Sci., 83(4): 582-586 (April 1994).	
	C80	Khamnei, "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs." *J. Med. Chem.*, 39: 4109-4115 (1996).	
	C81	Kim, et al., "A Novel Nucleoside Prodrug-Activating Enzyme: Substrate Specificity of Biphenyl Hydrolase-like Protein," Molecular Pharmaceutics (2004), 1(2), 117-127.	
	C82	Klumpp, et al., "The Novel Nucleoside Analog R1479 (4'-Azidocytidine) is a Potent Inhibitor of NS5B-dpendent RNA Synthesis and Hepatits C Virus Replication in Cell Culture." The Journal of Biological Chemistry, Vol. 281, No. 7, pp. 3793-3799, February 17, 2006.	
	C83	Kotra, L., et al., "Structure-Activity Relationships of 2'-Deoxy-2',2'-difluoro-L-erythro-pentofuranosyl Nucleosdes." J. Med. Chem. 1997, 40, 3635-3644.	
	C84	Kucera, et al., "Novel Membrane-Interactive Ether Lipid Analogs thath Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation." *AIDS Res. Hum. Retro Viruses*, 6: 491-501 (1990).	
	C85	Kuhn, R., et al., "Uber eine molekulare Umlagerung von N-Glucosiden." Jahrg. 69, 1936, p. 1745-1754.	
	C86	Kurtzberg J., et al., "Diferrential Toxicity of Carbovir and AZT to Human Bone Marrow Hematopoietic	

LAI-2913274v1

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Progenitor Cells in Vitro," Exp. Hematol., 18(10): 1094-1095 (1990).	
	C87	Lai, V.C.H., et al., "Mutational analysis of bovine viral diarrhea virus RNA-dependant RNA polymerase," J. Virol., 73(12):10129-101136 (December 1999).	
	C88	Landowski, "Nucleoside ester prodrug substrate specificity of liver carboxylesterase," Journal of Pharmacology and Experimental Therapeutics (2006), 316(2), 572-580.	
	C89	Leonard, et al., "5-Amino-5-deoxyribose Derivatives. Synthesis and Use in the Preparation of 'Reversed' Nucleosides." *J. Heterocycl. Chem.*, 3:485-489 (December 1966).	
	C90	Le Pogam, et al., "In Vitro Selected Con1 Subgenomic Replicons Resistant to 2'-C-Methyl-Cytidine or to R1479 Show Lack of Cross Resistance." Virology 351 (2006), 349-359.	
	C91	Le Pogam, et al., "Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymeras Inhibitors of the Hepatitis C Virus." Journal of Virology, Vol. 80, No. 12, June 2006, p. 6146-6154.	
	C92	Lerza, et al., "In Vitro Synergistic Inhibition of Human Bone Marrow Hemopoietic Progenitor Growth by a 3'-azido-3'doxy-thymidine, 2', 3'-dideoxycytidine Combindation." *Exp. Hematol.*, 25(3): 252-255 (1997).	
	C93	Lewis, et al., "Zidovudine Induces Molecular, Biochemical, and Ultrastructural Changes in Rat Skeletal Muscle Mitochondria." *J. Clin. Invest.*, 89(4): 1354-1360 (1992).	
	C94	Lewis, et al., "Ultrastructural Changes Associated with Reduced Mitochondrial DNA and Impaired Mitochondrial Function in the Presence of 2'3'-dideoxycytidine." *Antimicrob. Agents Chemother.*, 36(9): 2061-2065 (1992).	
	C95	Lewis, et al., "Fialuridine an Dits Metabolites Inhibit DNA Polymerase y at Sites of Ultiple Adjacent Analog Incorporationg, Decrease mtDNA Abundance, and Cause Mitochondrial Structural Defects in Cultured Hepatoblasts." *Proceedings of the National Academy of Science, USA*, 93(8): 3592-7 (1996).	
	C96	Li, et al., "2' –C-Branched ribonucleosides. 2. Synthesis of 2' –C-beta-trifluormethyl pyrimidine ribonucleosides," Org. Lett., vol. 3, 2001, pp. 1025-1028.	
	C97	Lin, T.S., et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," Tethrahedron Letters, 51(4): 1055-1068 (1995).	
	C98	Lohmann, et al., "Biochemical and Kinetic Analyses of NS5B RNA-dependent RNA Polymerase of the Hepatitis C Virus." *Virology*, 249, 108-118 (1998).	
	C99	Lopez Aparicio, F.J., et al., "Synthesis of Saccarinic Acid Derivatives," Carbohydrate Res., 129:99 (1984).	
	C100	Lopez-Herrera, F.J., et al., "A New Synthesis of 2-C Methyl-D-Ribono-1, 4-Lactone and the C-(/C-13 Fragment of Methynolide," J. Carbohydrate Chemistry, 13(5): 767-775 (1994).	
	C101	Luh, et al., "A Convenient Method for the Selective Esterification of Amino-Alcohols." *Synthetic Communications*, 8(5): 327-333 (1978).	
	C102	Maga, Giovanni, et al., Lack of stereospecificity of suid pseudorabies virus thymidine kinase," Biochem. J., 294(2): 381-385 (1993).	
	C103	Mahmoudian, M., et al., "A Versatile Procedure for the Generation of Nucleoside 5'-Carboxylic Acids Using Nucleoside Oxidase," Tetrahedron, Elsevier Science Publishers Amsterday, NL, vol. 54, no. 28, July 9, 1998.	
	C104	Mansour, T.S., et al., "Editorial," Anti-Ineffective Agents in Medicinal Chemistry, (2007) Vol. 6, No. 1, pp. 1.	
	C105	Markland W., et al., "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," Antimicrobial Agents and Chemotherapy, April 2000, Vol. 44, No. 4, pp. 859-866.	
	C106	Martin, J., et al., "Synthesis and Antiviral Activity of Monofluoro and Difluoro Analogues of Pyrimidine Deoxyribonucleosides Against Human Immnodeficiency Virus (HIV-1). J. Med. Chem. 1990, 33, 2137-2145.	
	C107	McCormick, J., et al., "Structure and Total Synthesis of HF-7, a Neuraoactive Glyconucleoside Disulfate from the Funnel-Web Spider Hololena curta," Journal of the American Chemical Society, 1999, Vol. 121, pp. 5661-5665.	
	C108	McKenzie, et al., "Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), An Investigational Nucleoside	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Analogue for Chronic Hepatitis B." *N. Engl. J. Med.*, 333(17): 1099-1105 (1995).	
	C109	Medina, et al., "Comparison of Mitochondrial Morphology, Mitochondrial DNA Content, and Cell Viability in Cultured Cell Treated with Three Anti-Human Immunodeficiency Virus Dideoxynucleosides." *Antimicrob. Agents Chemother.*, 38(8): 1824-8 (1994).	
	C110	Meier, et al., "Cyclic Saligenyl Phosphotriesters of 2', 3'-dideoxy-2', 3'-didehydrothymidine (d4T) – A New Pro-Nucleic Approach." *Bioorganic & Med. Chem. Letter*7(2): 99-104 (1997).	
	C111	The Merck Index, 12th edition, 1996, Page 275	
	C112	Meyer, et al, "2'-O-Acyl-6-Thioinosine Cyclic 3', 5'-phosphates as Prodrugs of Thioinosinic Acid." *J. Med. Chem.* 22: 811-815 (1979).	
	C113	Miles, et al., "Circular Dichroism of Nucleoside Derivatives. IX. Vicinal Effects on the Circular Dichrosim of Pyrimidine Nucleosides." J. Am. Chem. Soc. 92(13): 3872-3881 (1970).	
	C114	Moore, et al., "Synthesis of Nucleotide Analogues That Potently and Selectively Inhibit Human DNA Primase." Biochemistry (2002), 41(47), 14066-14075.	
	C115	Moiseyev, et al., "Determination of the nucleotide conformation in the productive enzyme-substrate complexes of RNA-depolymerases." FEBS Letters (1997), 404(2,3), 169-172	
	C116	Murai, et al., "A synthesis and an x-ray analysis of 2'-C-,3'-C- and 5'-C-methylsangivamycins," Heterocycles (1992), 33(1), 391-404.	
	C117	Neidlein, et al., "Mild Preparation of 1-benzyuloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Diesters and Cyclic Monoester Amides." *Heterocycles* 35: 1185-1203 (1993).	
	C118	Nishiguchi, S., et al., "Methods to Detect Substitutions in the Interferon-Sensitivity-Determining Region of Hepatitis C virus 1b for Prediction of Response to Interferon Therapy," Hepatology. January 2001, Vol. 33, No. 1, pp. 241-247.	
	C119	Nishimura, T. et al. "Studies on Sythetic Nuclesides. Trimethylsilyl Derivatives of Pyrmidine and Purines," Chemical & Pharmaceutical Bulletin (1964), vol. 12, pp. 352-356.	
	C120	Novak, J.J.K., "Chiroptical Properties of 2-Methyl-1,4-Lactones; Revised Absolute Configuration of 2-Deoxy-2-C-Methyl-Erythro-D-Pentono-1, 4-Lactones," Collection Czechoslav. Chem. Commun., 39:869-882 (1974).	
	C121	Novak, J.J.K. & Sorm, F., "Nucleic Acid Components and Their Analogues. CXX. 2-C-Methyl-D-Ribose and Its Derivatives," Collection Czechoslav. Chem. Commun., 34:857-866 (1969).	
	C122	Olsen, et al., (Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Rsearch (April 27, 2003, Savannah, Ga.) p. A76).	
	C123	Pagliaro, L., et al., "[Hepatology: Old, recent and (maybe) future stories. A narrative review]. EPATOLOGIA: IERI, OGGI E (FORSE) DOMANI," Recenti Progressi in Medicina, (2006) Vol. 97, No. 12, pp. 741-750.	
	C124	Piantadosi, et al, "Synthsis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity." *J. Med. Chem.* 34: 1408-1414 (1991).	
	C125	Pierra, C., et al., "Comparative Studies of Selected Potential Prodrugs of B-L-dC, A Potent and Selective Anti-HBV Agent," Antiviral Res., 50:A79 (2001), Abstract no. 138.	
	C126	Pierra, C., et al., "NM 283, and efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," Nucleosides, Nucleotides and Nucleic Acids (2005), 24(5-7), 767-770.	
	C127	Pierra, C., et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), and Efficient Prodrug of the Potent Anti-HCV Agent 2'-C-Methylcytidine," Journal of Medicinal Chemistry (2006), 49(22), 6614-6620.	
	C128	Reist, et al., "Potential anticancer agents. LXXVII. Synthesis of nucleosides of purine-6-thiol(6-mercaptopurine) containing "fraudulent" sugars." Journal of Organic Chemistry (1962), 27 3279-83.	
	C129	Richman, et al, "The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex." *N. Engl. J. Med.*, 317(4): 192-197 (1987).	
	C130	Robins, et al., "Purine Nucleosides. XXIX. The Synthesis of 2'-Deoxy-L-adenosine and 2'-Deoxy-L-guanosine and Their [alpha] Anomers," Journal of Organic Chemistry, 35(3), 636-639 (March 1970).	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C131	Rong, et al., "The Synthesis and Conformation of 2'-and 3'-Hypermodified Tricyclic Nucleosides and Their Use in the Synthesis of Novel 2'- or 3'-Isomeric 4(7)-Substituted Isoxazolidine-nucleosides," Tetrahedron Vol. 50, No. 16, pp. 4921-4936. (1994).	
	C132	Roque-Afonso, AM, et al., "Performance of TRUGENE hepatitis C virus5' noncoding genotyping kit, a new CLIP sequencing-based assay for hepatitis C virus genotype determination," Journal of Viral Hepatitis. September 2002, Vol. 9, Issue 5, pp. 385-389.	
	C133	Sakthivel, et al., "Direct SNAr amination of fluorinated imidazo[4,5- c]pyridine nucleosides: efficient syntheses of 3-fluoro-3deazaadenosine analogs." Tetrahedron Letters (2005), 46(22), 3883-3887.	
	C134	Sakthivel, et al. "Electrophilic fluorination of 5- (cyanomethyl)imidazole-4-carboxylate nucleosides: Facile entry to 3-fluoro-3- deazaguanosine analogues." Synlett (2005), (10), 1586-1590.	
	C135	Saladino, R., et al., "A new and efficient synthesis of cytidine and adenosine derivatives by dimethyldioxirane oxidation of thiopyrimidine and thiopurine nucleosides," J. chem. Soc., Perkin Trans. I., 21: 3053-3054 (1994).	
	C136	Sandhu, et al., "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range." Drug Metabolism and Disposition (2004), 32(11), 1254-1259	
	C137	Sato, et al., "C-Nucleoside synthesis. 10. Synthesis of 2'-methylated pyrimidine C-nucleosides." Tetrahedron Letters (1980), 21(20), 1971-4.	
	C138	Sato, et al., "C-Nucleoside synthesis. 19. Stereocontrolled general synthesis of pyrimidine C-nucleosides having branched-chain sugar moieties." Bulletin of the Chemical Society of Japan (1983), 56(9), 2680-99.	
	C139	Savochkina, et al., "Substrate properties of c – methylnucleoside triphosphates in RNA syntheses catalyzed by e. coli RNA – polymeruse" Molecular Biology, 1989, v. 23, no. 6.	
	C140	Schiff, E.R., "Emerging strategies for pegylated interferon combination therapy," Nature Clinical Practice Gastoenterology and Hepatology, (2007) Vol. 4, No. SUPPL. 1, pp. S17-S21.	
	C141	Schmit, C., et al., "Synthesis of 2'-Deoxy-2' –Alpha-Monofluoromethyl and Trifluoromethylnucleosides," Synlett, Thieme Verlag, Stuttgart, DE, no. 4, 1994, pp. 241-242.	
	C142	Shim, Jae H., "Recent patents on nucleoside and nucleotide inhibitors for HCV," Recetn Patents on Anti-Infective Drug Discovery (2006), 1(3), 323-331.	
	C143	Smith, et al., "Synthesis of new 2'-β-C-methyl related triciribine analogues as anti-HCV agents." Valeant Pharmaceuticals International, Costa Mesa, CA, USA. Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3517-3520.	
	C144	Song, et al., Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevasion, and hPEPT1-Medicated Transport," Molecular Pharmaceutics (2005), 2(2), 157-167.	
	C145	Sorbera, L.A., et al., "Valopicitabine: anti-hepatitis C virus drug RNA –directed RNA polymerase (NS5B) inhibitor," Drugs of the Future (2006), 31 (4), 320-324.	
	C146	Sowden, J., "The Saccharinic Acids," Adv. Carbohydrate Chem., 12:43-46 (1957).	
	C147	Spardari, et al., "L-Thmidine is Phosphorylated by Herpes Simplex Virus Type 1 Thymidine Kinase and Inhibits Viral Growth," Journal of Medicinal Chemistry, 35(22), 4214-4220 (1992).	
	C148	Standring, D.N., et al., "Antiviral Beta-L-Nucleosides Specific for Hepatitis B Virus Infection," Antiviral Chem. & Chemother., 12 (Suppl. 1): 119-129 (2001).	
	C149	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and In Vitro Evaluation of Prodrugs of the Antiviral Agents 9-(2-(phosphonomethoxy)ethyl)adenine (PMEA)." *J. Med. Chem.* 37: 1857-1864 (1994).	
	C150	Stuyver, et al., "Ribonucleoside Analogue That Block Replication of Bovine Viral Diarrhea and Hepatits C Viruses in Culture." Antimicrobial Agents and Chemotherapy, Vol 47, No. 1, Jan. 2003, p. 244-254.	
	C151	Takenuki, et al., "Nucleosides and nucleotides. XLIII. On the stereoselectivity of alkyl addition reaction of pyrimidine 2'-ketonucleosides." Chemical & Pharmaceutical Bulletin (1990), 38(11), 2947-52.	
	C152	Tang, X.-Q., et al., "2'-C-Branched Ribonucleosides: Synthesis of the Phophoramidite Derivatives of 2'-C-B-	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Methylcytidine and Their Incorporation into Oligonucleotides," J. Org. Chem., 64(3): 747-754 (1999).	
	C153	Tronchet, et al. "72. Synthese et desamination enzymatique des C-hydroxymethyl-3'-et C-methyl-3' –beta-D-xylofurannosyl-9-adenin es," Helv. Chim. Acta, vol. 62, 1979, pp. 689-695.	
	C154	Tyrsted, G., et al., "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxyadenosine and structurally related nucleoside analogs," Biochem. Biophys. Acta., 155(2): 619-622 (February 26, 1968).	
	C155	Vassilev, V., et al., "Bovine Viral Diarrhea Virus Induced Apoptosis Correlates with Increased Intracellular Viral RNA Accumulation." *Virus Research*, 69: 95-107 (2000).	
	C156	Velazquez, et al., "Synthesis of '1-'3',5'-bis-0-(tert-butyldimethylsily)-beta-D-arabino-and beta-D-ribofuransoyl cytosine-2' –spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide). Analogues of the highly specific anti-HIV-1 agent TSAO-T," Tetrahedron, vol. 50, 1994, pp. 11013-11022.	
	C157	Verri, A., et al., "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activetion of B-L-deoxyctidine analogs as antineolastic and antiviral agents," Molecular Pharmacology, 51(1): 132-138 (January 1997).	
	C158	Verri, a., et al., "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Knase and Chemotherapeutic Uses of L-Nucleoside Analogues," Biochem. J., 328(1): 317-320 (November 15, 1997).	
	C159	Von Buren, et al., "Branched oligodeoxynucleotides: automated synthesis and triple helical hybridization studies." Tetrahedron (1995), 51(31), 8491-506.	
	C160	Von Janta-Lipiniski, M., et al., "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified B-2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular SNA Polymerases a, B, y, d and E Nor HIV-1 Reverse Transciptase," J. Medicinal Chemistry, 41(12): 2040-2046 (May 21, 1998).	
	C161	Wagner, D., et al., "Preparation and Synthetic Utility of Some Organotin Derivatives of Nucleosides," J. Org. Chem., 39(1):24-30 (1974).	
	C162	Weinberg, et al., "Effect of Antiviral Drugs and Hematopoietic Growth Factors on In Vitro Erythropoiesis." *Mt. Sinai J. Med.* 1998; 65(1): 5-13.	
	C163	Whistler, R. L., and BeMiller, J.N., "[118] 'a'-D-Glucosaccharino-1,4-Lactone," Methods in Carbohydrate Chemistry, 2:484-485 (1963).	
	C164	Wohnsland, A., et al., "Viral determinants of resistance to treatment in patients with hepatitis C," Clinical Microbiology reviews, (2007) Vol. 20, No. 1, pp. 23-38.	
	C165	Wolf, et al., "New 2' –C-Branched-Chain Sugar Nucleoside Analogs With Potential Antiviral or Antitumor Activity," Synthesis, Georg Thieme Verlag. Stuttgart, DE, no. 8, August 1992 (1992-08), pp. 773-778.	
	C166	Yarchoan, et al, "Long-Term Toxicity / Activity Profile of 2', 3'-dideoxyinosine in AIDS or AIDS-Related Complex." *The Lancet*, 336 (8714): 526-529 (1990).	
	C167	Yoshida, et al., "Reversal of Azidothymidine-Induced Bone Marrow Suppression by 2', 3'-Dideoxythmidine as Studied by Hemopoietic Clonal Culture." *AIDSi Res. Hum. Retroviruses*, 6(7): 929-932 (1990).	
	C168	Zemlicka, J., et al. "Aminoacyl Derivatives of Nucleosides, Nucleotides, and polynucleotides. VIII. The Preparation of 2'(3) –O-L-Phenylalanyluridine, -cytidenie, - Adensonine, -inosine, -guanosine and 2'-Deoxy-3' O-L-Phenylalanyladenosine," Collection Czecoslov, Chem. Commun. 1969, Vol. 43, No. 13.	
	C169	Zemlicka, J., et al., "Substrate Specificity of Ribosomal Peptidyltransferase. Peditidyltranferase. Effect of Modifications in the Heterocyclic, Carbohydrate and Amino Acid Moiety of 2'(3)-O-L-Phenyladenosine." Biochemistry. December 2, 1975, Vol. 14, No. 24.	
no date provided	C170	Zintchenko, et al., 2', 3' & 5' uridine methyl derivatives in microbiological transglicozilation." Doklady Akad Nauk v.297(3), pp. 731-734.	
	C171	Zintchenko, et al., "Substrate Specificity of Uridine and Purine Nucleoside Phosphorylases of the Whole Cells of Escherichia Coli." Nucleic Acids Research, Symposium Series No. 18., 1987, pp. 137-140.	
	C172	Zintchenko, et al., "Substrate specificity of uridine and purine nucleoside phosporlases in whole cells of e. coli" Bioplymers & a cell, 1988, v. 4, No. 6.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-044-999	10/602,142
	APPLICANT	CONFIRMATION NO.
	Sommadossi *et al.*	8280
	FILING DATE	ART UNIT
	June 20, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C173	Zon, "Cyclophosphamide Analogues." Chapter 4 in *Progress in Medicinal Chemistry*, Vol. 19, G. P., Ellis and G. B. West, Eds., pp. 205-246 (1982).	

EXAMINER	/Traviss Mcintosh III/ (02/19/2008)	DATE CONSIDERED	02/19/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TM/